Advertisement

Topics

Samsung Bioepis Co., Ltd. Company Profile

06:57 EDT 30th April 2017 | BioPortfolio

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to increasing patient access to affordable, high-quality biologic medicines. Through innovations in product development and quality assurance, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.


News Articles [234 Associated News Articles listed on BioPortfolio]

Samsung Bioepis to take on J&J with FDA approved Remicade biosimilar

Samsung Bioepis’ Renflexis has become the second biosimilar of rheumatoid arthritis biologic Remicade (infliximab) to be recommended for approval in the US.

FDA approves Samsung Bioepis' copy of J&J's Remicade: company

SEOUL (Reuters) - South Korea's Samsung Bioepis Co Ltd said on Saturday the U.S. Food and Drug Administration approved its copy of Johnson & Johnson's rheumatoid arthritis drug Remicade, the first dru...

Samsung Bioepis receives US FDA approval for Renflexis across all eligible indications

Samsung Bioepis Co., Ltd. announced that the US Food and Drug Administration (FDA) has approved Renflexis (infliximab─abda), a biosimilar referencing Remicade (infliximab), across all eligible indic...

Samsung Bioepis’s Biosimilar Enbrel ‘Substitutable’ In Australia As Pfizer Patent Case Is Rebuffed

Samsung Bioepis’s Brenzys is the latest biosimilar to be reimbursed as substitutable at the pharmacy level in Australia, and a...   

Samsung Bioepis receives FDA approval for Renflexis across all eligible indications

Samsung Bioepis has received the US Food and Drug Administration (FDA) approval for its biosimilar referencing Remicade (infliximab), Renflexis (infliximab-abda), across all eligible indications.

Samsung Bioepis’ Biosimilar Version of Remicade Receives FDA Approval

INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved RENFLEXIS™ (infliximab-abda), a biosimilar referencing R...

Samsung wins FDA approval for Remicade biosimilar

South Korea-based Samsung Bioepis' Renflexis has been approved by the FDA as a treatment for rheumatoid arthritis and other i -More- 

Samsung Bioepis Obtains First Drug Approval in the United States, as the U.S. Food and Drug Administration Approves RENFLEXIS™ (Infliximab-abda) Across All Eligible Indications

Monday, April 24th 2017 at 5:06am UTC INCHEON, Korea–(BUSINESS WIRE)– Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved RENFLEXIS™ (...

Drugs and Medications [0 Results]

None

PubMed Articles [7 Associated PubMed Articles listed on BioPortfolio]

Clinical outcomes of tissue expanders on adjuvant radiotherapy of resected retroperitoneal sarcoma.

We investigated the efficacy and safety of a tissue expander (TE) for adjuvant radiotherapy (RT) of resected retroperitoneal sarcoma (RPS).This study was conducted with 37 patients with RPS who receiv...

Examining Authenticity: An Initial Exploration of the Suitability of Handwritten Electronic Signatures.

Considering the increasing relevance of handwritten electronically captured signatures, we evaluated the ability of forensic handwriting examiners (FHEs) to distinguish between authentic and simulated...

Natural course of untreated cluster headache: A retrospective cohort study.

Objective To determine the natural course of cluster headache. Methods We screened patients with cluster headache who were diagnosed at Samsung Medical Center and lost to follow-up for ≥5 years. Eli...

Tissue expander placement and adjuvant radiotherapy after surgical resection of retroperitoneal liposarcoma offers improved local control.

Given that retroperitoneal liposarcoma (LPS) is extremely difficult to completely resect, and has a relatively high rate of recurrence, radiotherapy (RT) is the treatment of choice after surgical rese...

Tissue expander placement and adjuvant radiotherapy after surgical resection of retroperitoneal liposarcoma offers improved local control.

Given that retroperitoneal liposarcoma (LPS) is extremely difficult to completely resect, and has a relatively high rate of recurrence, radiotherapy (RT) is the treatment of choice after surgical rese...

Clinical Trials [14 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting

To establish the performance characteristics of the Samsung LABGEO IVD-A20 CHF Test in intended use settings, by comparing test results of the A20 CHF Test with results obtained from an FD...

Gait Pattern Analysis and Feasibility of Gait Training With a Walking Assist Robot in Stroke Patients and Elderly Adults

The purpose of this study was to investigate the effects of the new wearable hip assist robot developed by Samsung Advanced Institute of Technology (Samsung Electronics Co, Ltd., Korea) to...

The Effect of a Walking Assist Robot on Gait Function and Brain Activity in Stroke Patients and Elderly Adults

The purpose of this study was to investigate the effects of the new wearable hip assist robot, gait enhancing mechatronic system (GEMS) developed by Samsung Advanced Institute of Technolog...

Samsung Medical Center-Lymphoma Cohort Study

The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.

Database of Pelvic Inflammatory Disease

The aim of this prospective study is to collect data on in-patients with pelvic inflammatory disease(PID) at Kangbuk Samsung Hospital.

Companies [22 Associated Companies listed on BioPortfolio]

Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to increasing patient access to affordable, high-quality biologic medicines. Through innovations in p...

Samsung Electronics America

Samsung Electronics America, Inc. (SEA), based in Ridgefield Park, NJ, is a subsidiary of Samsung Electronics Co., Ltd. The company markets a broad range of award-winning consumer...

Samsung Electronics North America

Samsung Electronics North America (NAHQ), based in Ridgefield Park, NJ, is an arm of Samsung Electronics Co., Ltd. The company markets a broad range of award-winning consumer elec...

Samsung Electronics America, Inc.

Samsung Electronics America, Inc. (SEA), based in Ridgefield Park, NJ, is a subsidiary of Samsung Electronics Co., Ltd. The company markets a broad range of award-winning consumer...

Samsung Electronics America Inc.

As a global leader in Information Technology, Samsung’s Enterprise Business Division (EBD) is committed to introducing new business experiences across a diverse spectrum of i...

More Information about "Samsung Bioepis Co., Ltd." on BioPortfolio

We have published hundreds of Samsung Bioepis Co., Ltd. news stories on BioPortfolio along with dozens of Samsung Bioepis Co., Ltd. Clinical Trials and PubMed Articles about Samsung Bioepis Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Samsung Bioepis Co., Ltd. Companies in our database. You can also find out about relevant Samsung Bioepis Co., Ltd. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record